Prot #R10933-10987-COV-2066: A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients with COVID 19

Project: Research project

Project Details

StatusFinished
Effective start/end date7/22/20 → 7/22/23

Funding

  • Parexel (Prot #R10933-10987-COV-2066 // Prot #R10933-10987-COV-2066)
  • Regeneron Pharmaceuticals, Inc. (Prot #R10933-10987-COV-2066 // Prot #R10933-10987-COV-2066)